4-(3-methylcarbamoyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester | 828243-29-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(3-methylcarbamoyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-[3-(methylcarbamoyl)phenyl]piperidine-1-carboxylate
• CAS: 828243-29-4
• 化学式: C₁₈H₂₆N₂O₃
• 分子量: 318.416
• InChiKey: FHLZMRXIFMGDJQ-UHFFFAOYSA-N

物化性质

• 沸点：
  468.4±45.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-methylcarbamoyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 反应 2.0h， 以98%的产率得到N-甲基-3-(哌啶-4-基)苯甲酰胺
  参考文献：
  名称：

  Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities

  摘要：

  A new series of thiazole-substituted 1,1,1,3,3,3-hexafluoro-2-propanols were prepared and evaluated as malonyl-CoA decarboxylase (MCD) inhibitors. Key analogs caused dose-dependent decreases in food intake and body weight in obese mice. Acute treatment with these compounds also led to a drop in elevated blood glucose in a murine model of type II diabetes. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.08.047
• 作为产物：
  描述：

  4-(3-methylcarbamoyl-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以99%的产率得到4-(3-methylcarbamoyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] MEDICINAL USE OF RECEPTOR LIGANDS
  [FR] UTILISATION MEDICALE DE LIGANDS RECEPTEURS

  摘要：

  公开号：

  WO2006010446A3

文献信息

• MEDICINAL USE OF RECEPTOR LIGANDS
  申请人：Receveur Jean-Marie

  公开号：US20090062317A1

  公开（公告）日：2009-03-05

  Compounds of formula (I) are ligands of the melanin concentrating hormone-1 receptor (MCH-1R), useful in the treatment of diseases responsive to modulation of melanin concentrating hormone (MCH) activity, for example feeding disorders and diseases for which obesity is a risk factor (I): wherein ring B is selected from specific substituted phenyl or benz-fused 5 membered N-containing heterocycles defined in the specification; R, is attached to a ring carbon of ring B, and represents hydrogen, F, Cl, or —OCH 3 ; X is ═CH— or ═N—; L, is —CH 2 — or —CH 2 CH 2 —; L 2 is a bond, —CH 2 — or —CO—; R2 is H or C, —C 3 alkyl, or —N(R 2 ) L, —is selected from specific cyclic amino linker radicals as defined in the specification; ring A is selected from specific N-containing heterocyclic rings as defined in the specification.

  式(I)的化合物是黑素浓集激素-1受体(MCH-1R)的配体，可用于治疗对黑素浓集激素(MCH)活性调节敏感的疾病，例如进食障碍和肥胖是危险因素的疾病（式(I)）：其中环B选自规定的特定取代苯基或苯并5元杂环；R附着在环B的环碳上，表示氢，F，Cl或—OCH3；X为═CH—或═N—；L为—CH2—或—CH2CH2—；L2为键，—CH2—或—CO—；R2为H或C，—C3烷基，或—N(R2)L，—选自规定的特定环状氨基连接基团。环A选自规定的特定含氮杂环。
• Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities
  作者：Haifeng Tang、Yan Yan、Zhe Feng、Reynalda K. de Jesus、Lihu Yang、Dorothy A. Levorse、Karen A. Owens、Taro E. Akiyama、Raynald Bergeron、Gino A. Castriota、Thomas W. Doebber、Kenneth P. Ellsworth、Michael E. Lassman、Cai Li、Margaret S. Wu、Bei B. Zhang、Kevin T. Chapman、Sander G. Mills、Joel P. Berger、Alexander Pasternak

  DOI：10.1016/j.bmcl.2010.08.047

  日期：2010.10

  A new series of thiazole-substituted 1,1,1,3,3,3-hexafluoro-2-propanols were prepared and evaluated as malonyl-CoA decarboxylase (MCD) inhibitors. Key analogs caused dose-dependent decreases in food intake and body weight in obese mice. Acute treatment with these compounds also led to a drop in elevated blood glucose in a murine model of type II diabetes. Published by Elsevier Ltd.
• [EN] MEDICINAL USE OF RECEPTOR LIGANDS<br/>[FR] UTILISATION MEDICALE DE LIGANDS RECEPTEURS
  申请人：7TM PHARMA AS

  公开号：WO2006010446A3

  公开（公告）日：2006-05-18